New clinical trials involving CAR-NK cells are on the rise globally, including Dual CAR-NK19/70 trials for R/R B-cell lymphomas and advanced solid tumors (NCT05842707 and NCT05703854), TROP2-CAR-NK (TROP2-CAR engineered IL15-transduced CB-NK cells) trials (NCT06066424 and NCT05922930) for advanced solid cancers, NKG2D CAR-NK trial for ovarian cancer (NCT05776355), and Anti-CD19 CAR-NK (KN5501) trial for Systemic Lupus Erythematosus (SLE) (NCT06010472). This evidence concerns the gene TACSTD2 and B-cell non-Hodgkin lymphoma.